Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...

Chemotherapy drugs that target cancer cells without damaging normal cells remain one of the key goals of precision medicine ...

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma. In part 1 of our interview with ...

Glioblastoma is the most common and most aggressive primary brain tumor, with an average survival after diagnosis of less than two years, and against which current treatments remain ineffective. In ...

Balancing the immune system is a delicate act. If it’s too weak, infections and cancer can take hold; if it’s too strong, autoimmune diseases or transplant rejection can occur. Researchers have ...

HIV infects immune cells and establishes long-lasting infections that can progress to acquired immunodeficiency syndrome (AIDS) if left untreated. With the advancement of antiviral therapy (ART), HIV ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...

Engineered dendritic cells capture tumor EVs, enhancing antigen presentation and T cell activation to boost cancer immunotherapy in preclinical models.

An Autolus Therapeutics cell therapy has won FDA approval for treating an aggressive blood cancer. It’s the biotech’s first approved product and just the second CAR T-treatment for adults who have ...

In a potentially major breakthrough for regenerative medicine, scientists at MIT have developed a way to convert skin cells directly into brain cells extremely efficiently, without needing to go ...